- Pfizer Inc PFE reports Q2 adjusted EPS of $1.07, well ahead of the consensus of $0.96 and 73% Y/Y higher from $0.62 posted a year ago.
- The Company achieved Q2 revenues of $18.9 billion, +92% Y/Y, reflecting operational growth of $8.5 billion, or +86%, surpassing the Wall Street estimate of $18.4 billion.
- Excluding the COVID-19 vaccine sales of $7.8 billion, revenues grew 10% operationally to $11.1 billion.
- FY21 Outlook: The Company raised its full-year 2021 revenue outlook to $78 billion - $80 billion (consensus of $72.78 billion), from the prior %70.5 billion - $72.5 billion.
- It expects EPS of $3.95-$4.05 (consensus- $3.70), higher than the previous outlook of $3.55 - $3.65.
- Pfizer has raised its revenue expectation from the COVID-19 vaccine by almost $7.5 billion to approximately $33.5 billion, reflecting 2.1 billion doses expected to be delivered in 2021 under signed contracts.
- Price Action: PFE shares are down 0.21% at $42.01 during the premarket session on the last check Wednesday.
- Image by x3 from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in